<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01172548</url>
  </required_header>
  <id_info>
    <org_study_id>CSTI571BIC08</org_study_id>
    <nct_id>NCT01172548</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Evaluation of Two Year Imatinib Treatment in Adjuvant Gastrointestinal Stromal Tumor (GIST)</brief_title>
  <acronym>INV555</acronym>
  <official_title>A Multi-center, Single Arm, Phase II Study of Adjuvant Imatinib (Glivec®) in Patients Following the Resection of Primary Gastrointestinal Stromal Tumor ( GIST)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      GISTs are the most common mesenchymal tumors of the gastrointestinal tract. Approximately 95%
      of GISTs are positive for KIT (CD117)-the receptor for stem cell factor (SCF). GISTs are not
      responsive to conventional cytotoxic chemotherapy and disease often recurs even after
      complete resection with wide margins.

      Imatinib mesylate (trade names: Glivec® and Gleevec®, imatinib, formerly STI571) is a signal
      transduction inhibitor targeting several protein-tyrosine kinases that are believed to play a
      role in the proliferation of tumor cells. In the Phase II study of imatinib [CSTI571B 2222]
      in 147 patients with recurrent or metastatic GIST, the partial response rates were 67% and
      66% in patients treated at 400 mg/d and 600 mg/d, respectively. Skin rash and elevated
      transaminases were the most common reason for drug discontinuation. The most frequently
      reported AEs were mild nausea, vomiting, diarrhea, superficial edema (primarily periorbital
      or lower limb), myalgia and muscle cramps. Grade 3/4 events included fluid retention (pleural
      or pericardial effusions, ascites, and pulmonary edema), skin rash, liver toxicity and
      gastrointestinal (GI) hemorrhage. Myelosuppression (neutropenia and thrombocytopenia) was a
      consistent finding. Also, a tumor lysis-like syndrome occurred in some patients leading to
      gastrointestinal (GI) and/or intratumoral hemorrhage.

      In a Phase 3, American College of Surgeons Oncology Group trial (ACOSOG Z9001) of adjuvant
      imatinib, imatinib significantly improved 1-year recurrence-free survival (RFS) compared with
      placebo.

      In summary, clinical trials have shown that imatinib produces clinical benefit in most
      patients with unresectable or metastatic GIST and extends median survival from 19 to 57
      months. Imatinib is the standard of care for advanced GIST and has received regulatory
      approval for the treatment of unresectable or metastatic GIST. Studies suggest that adjuvant
      imatinib for 1 year prolongs RFS in patients at high risk of recurrent disease and metastases
      following complete surgical resection of the primary GIST.

      Imatinib is an appealing adjuvant therapy for resected GIST because:

        1. Patients with primary GIST have a high chance of tumor recurrence

        2. Conventional adjuvant treatment modalities are ineffective

        3. Imatinib specifically inhibits the Kit receptor which is constitutively activated in
           most GISTs

        4. Imatinib inhibits the growth of Kit positive cells in vitro

        5. Imatinib is highly effective in many patients with advanced GIST in a Phase II trial

        6. Imatinib has been associated with minimal toxicity in patients with advanced GIST and in
           patients with chronic myelogenous leukemia (CML)

        7. Imatinib may have its greatest impact on survival when there is minimal disease.

      Primary

        -  To assess Recurrence Free Survival Rate in patients with resected primary GIST who are
           treated with adjuvant imatinib for a duration of 2 years Secondary

        -  To compare Recurrence Free Survival, Overall Survival, and Time to Recurrence of
           patients with resected primary GIST who are treated with adjuvant imatinib for a
           duration of 2 years with historical data To assess the safety of imatinib given as
           adjuvant therapy for 2 years in patients with resected primary GIST
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence Free Survival Rate</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare Recurrence Free Survival Rate to historical controls</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare Overall Survival to historical controls</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare Time To Recurrence to historical controls</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Compliance - tracking if the patient is coming to visits as per visit schedule in protocol</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">132</enrollment>
  <condition>Gastrointestinal Stromal Tumors</condition>
  <arm_group>
    <arm_group_label>imatinib mesylate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>imatinib mesylate</intervention_name>
    <arm_group_label>imatinib mesylate</arm_group_label>
    <other_name>STI571</other_name>
    <other_name>Gleevec/Glivec</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven diagnosis of primary GIST (without peritoneal or distant
             metastasis) with positive immunostaining for KIT (CD117);

          -  Undergone complete gross resection of a primary GIST within 70 days prior to
             enrollment (includes R0 [negative microscopic margins] and R1 [positive microscopic
             margins]);

          -  Intermediate or high risk of recurrence based on Corless criteria (Section 5.1):

        Exclusion Criteria:

          -  Patient has received prior therapy with imatinib, or any other molecular targeted or
             biological therapy.

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Alger</city>
        <zip>016000</zip>
        <country>Algeria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mansoura</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujrat</state>
        <zip>380009</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411 001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mumbai</city>
        <zip>400016</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New Delhi</city>
        <zip>110044</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amman</city>
        <country>Jordan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beirut</city>
        <zip>1107 2020</zip>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kazan</city>
        <state>Tatarstan Republic</state>
        <zip>420029</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Irkutsk</city>
        <zip>664035</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kursk</city>
        <zip>305035</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Omsk</city>
        <zip>644013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>198255</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Riyadh</city>
        <zip>11211</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Parktown</city>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tainan 704</city>
        <state>Taiwan ROC</state>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <state>Taiwan, ROC</state>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lin-Ko</city>
        <zip>33305</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Niaosong Township</city>
        <zip>83301</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Songkla</city>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tunis</city>
        <zip>1006</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Algeria</country>
    <country>Egypt</country>
    <country>India</country>
    <country>Jordan</country>
    <country>Lebanon</country>
    <country>Russian Federation</country>
    <country>Saudi Arabia</country>
    <country>South Africa</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>Tunisia</country>
    <country>Turkey</country>
  </location_countries>
  <removed_countries>
    <country>Morocco</country>
  </removed_countries>
  <link>
    <url>http://meetinglibrary.asco.org/content/92196-114</url>
    <description>J Clin Oncol 30, 2012 (suppl; abstr e20514) (From 2012 ASCO Annual Meeting )</description>
  </link>
  <link>
    <url>https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=16291</url>
    <description>See results for CSTI571BIC08 at Novartis Clinical Trials Database</description>
  </link>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2010</study_first_submitted>
  <study_first_submitted_qc>July 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2010</study_first_posted>
  <last_update_submitted>May 28, 2017</last_update_submitted>
  <last_update_submitted_qc>May 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Resected GIST</keyword>
  <keyword>primary GIST</keyword>
  <keyword>tumor recurrence</keyword>
  <keyword>KIT receptor</keyword>
  <keyword>KIT positive</keyword>
  <keyword>advanced GIST</keyword>
  <keyword>minimal toxicity</keyword>
  <keyword>GIST</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

